Abstract |
The aims of this study were to investigate the prevalence of ED in Chinese men with type 2 diabetes mellitus, and evaluate the efficacy and safety of sildenafil citrate in these patients. Patients from 42 outpatient diabetes clinics with type 2 diabetes mellitus and ED as defined by the International Index of Erectile Function (IIEF)-5 were studied. Participants with ED received three doses (100 mg each) of sildenafil citrate for use over 3 months. Efficacy of sildenafil citrate was assessed using the IIEF-5 and the Global Efficacy Questionnaire (GEQ). Adverse events were recorded by patients in a daily diary. A total of 5477 participants were evaluated, and 75.2% had ED. Age, duration of diabetes and glycosylated hemoglobin (HbA(1)c) >6.5% were independently and significantly associated with the presence and degree of ED. Patients who received pharmacotherapy (N=389) reported significant improvements. The rate of erections as determined by the GEQ was also significantly improved following treatment. ED is a common complication in Chinese men with type 2 diabetes mellitus, and certain risk factors are associated with the presence of ED and severity. Sildenafil citrate is a safe and effective treatment for these patients.
|
Authors | G Yang, C Pan, J Lu |
Journal | International journal of impotence research
(Int J Impot Res)
2010 Sep-Oct
Vol. 22
Issue 5
Pg. 310-7
ISSN: 1476-5489 [Electronic] England |
PMID | 20811390
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Phosphodiesterase 5 Inhibitors
- Piperazines
- Purines
- Sulfones
- Sildenafil Citrate
|
Topics |
- Adult
- Aged
- Asian People
(statistics & numerical data)
- Diabetes Mellitus, Type 2
(ethnology)
- Erectile Dysfunction
(drug therapy, ethnology)
- Humans
- Logistic Models
- Male
- Middle Aged
- Phosphodiesterase 5 Inhibitors
(therapeutic use)
- Piperazines
(therapeutic use)
- Prevalence
- Purines
(therapeutic use)
- Risk Factors
- Sildenafil Citrate
- Sulfones
(therapeutic use)
- Surveys and Questionnaires
|